GMP News, GMP guidelines, GMP Violations, GMP warnings A Public Health Global News Portal

Welcome to gmpviolations.com FDA, WHO, EU, TGA, CDSCO guidelines...and GMP Violations news/warning letters..

150000+ Industry Leaders already read it everyday

Wednesday, October 26, 2016

GSK files potential $1 billion shingles vaccine for U.S. approval

Shingrix is viewed by analysts as among the British company's most promising experimental products, since it has shown greater protection among older recipients than Merck & Co's rival shot Zostavax.



By Ben Hirschler
LONDON: GlaxoSmithKline has filed its shingles vaccine Shingrix for U.S. regulatory approval, the drugmaker said on Monday, bringing the potential $1 billion-a-year seller a step closer to market.
Shingrix is viewed by analysts as among the British company's most promising experimental products, since it has shown greater protection among older recipients than Merck & Co's rival shot Zostavax.
GSK itself highlighted Shingrix as one of its top near-term pipeline hopes last November, during its first research and development day in more than a decade.
The company, which will see Emma Walmsley take over as chief executive in 2017, is seeking to revitalise a drug portfolio hit by falling sales of best-selling inhaled lung treatment Advair.
In clinical trials, GSK's vaccine remained 90 percent effective in people over age 70, even four years after injections. Zostavax efficacy, by contrast, varies between 18 and 70 percent, and it declines noticeably in older people.
People who are 70 years or older are often most at risk from shingles, a painful, itchy rash that results from the reactivation of latent chickenpox virus.
The impressive trial results should put Shingrix in a strong competitive position, analysts believe, even though it requires two doses, against just one for Zostavax, and it is also linked to more injection site reactions.
Analysts, on average, predict that worldwide sales of Shingrix will reach 856 million pounds ($1.05 billion) in 2021, according to consensus forecasts compiled by Thomson Reuters.
Sales of Zostavax, the only shingles vaccine on the market at present, totalled $749 million in 2015.
GSK's vaccine contains a component from U.S. biotech firm Agenus, which is entitled to royalties on future sales.
GSK said it planned to file Shingrix for European and Canadian approval before the end of this year, with Japan following in 2017.
($1 = 0.8191 pounds)(Editing by Susan Fenton and Jason Neely)

www.gmpviolations.com (This story has not been edited by GMP Violations staff and is auto-generated from a syndicated feed.)

 Disclaimer: The Logos/Images posted here are belongs to respective to Authority / owners of firm.
Share:

0 comments:

Post a Comment

Related Posts Plugin for WordPress, Blogger...

AMAZON BEST DEALS

Popular Posts

AMAZON BEST DEALS

Subscribe Free GMP Guidelines

Enter your email address:

Delivered by FeedBurner

Followers

Printfriendly

Subscribe via email for free

Services

Enter your email address:

Delivered by FeedBurner

Contact Form

Name

Email *

Message *

Menu :
Powered by Blogger.

Visitors

    Translater

    Related Posts Plugin for WordPress, Blogger...

    Category

    2016 (37) 2017 (85) 2018 (9) 211 CFR (1) 211.63 (1) 483 (5) AAFA (1) Abbott (2) AboutUs (1) ALCOA (1) Alerts (2) ANDA (1) Anshu (2) Antibiotics (1) apic (1) APR17 (8) APS (2) Articles (4) AstraZeneca (1) Aug17 (2) Aurobindo (2) Author (2) Authors (8) Biocon (1) cadila (1) capa (3) CDSCO (5) Change control (1) Christian Green (1) cipla (2) Cleaning validation (1) Data Integrity (9) dec16 (15) Definations (1) Deviations (1) Donald Trump’s (2) Downloads (17) Dr.Reddy's (4) eca (1) EIR (1) Eli Lilly (1) ema (12) EU (9) FDA (70) FDA Guide (18) FEB17 (15) Genaral (1) General Health (2) GMP (1) GMP News (36) gsk (2) GuidelineEU (10) GuidelinesG (5) GuidelineW (2) GV/0117/001 (1) GVAuthors (3) Health (4) HOSPIRA (1) ICH (3) ICHGuide (3) import alert (1) India (1) ISPE (1) James Bullock (1) JAN17 (23) Jul17 (8) July17 (1) Jun17 (4) Lupin (2) Mahender (39) MAR17 (13) Mar18 (7) May17 (10) MHRA (3) MHRA guide (1) Mumbai (1) Mylan (4) Natco (1) News (55) Non Complinaces (1) Nov16 (5) Novartis (1) oct (1) Oct16 (10) OCT17 (1) PDA (1) Personnel (1) pfizer (1) pics (8) Picsguide (2) QbD (1) Quality Docs (1) RCA (1) Recall (1) safety (1) Sanjeev Kumar Singh (4) Sanofi (1) Sep16 (6) Siegfried Schmitt (2) SUN (1) TGA (3) TOP 10 PHARMA (1) USP (2) Validation (3) Warning Letters (43) WHO (6) zika (1)

    Sponsors

    Theme Support